Press Releases

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May, 09 2024

Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter Phase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and will evaluate VYN201 gel in 1%, 2% and 3% concentrations compared to vehicle for 24 weeks, followed by a 28-week active treatment extension IND clearance received for oral BD2-selective BET inhibitor, VYN202; anticipate first healthy volunteers to be dosed in Phase 1a SAD/MAD trial this quarter BRIDGEWATER, N.J., May 09, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage…

Read More

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May, 06 2024

In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD trial expected to start this quarter BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the clearance of its Investigational New Drug application (“IND”) by the U.S. Food and Drug Administration for VYN202, an oral BD2-selective BET inhibitor. VYNE plans to initiate a first-in-human Phase 1a…

Read More

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

May, 01 2024

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA. “We look forward to sharing our preclinical and Phase 1b data for…

Read More

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

February, 29 2024

2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024 Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash and marketable securities, providing runway through the end of 2025 and multiple expected clinical milestones BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated…

Read More

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

February, 27 2024

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024. “We are…

Read More

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February, 21 2024

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2024. Management will also be available for 1-on-1 meetings with investors. 44th Annual TD Cowen Health Care Conference Presentation Details Fireside Chat: Monday, March 4, 2024, at 10:30 a.m. ET…

Read More